Mlađjan Golubović1, Radmilo Janković1,2, Dušan Sokolović2, Vladan Ćosić3, Vera Maravić-Stojkovic4, Tomislav Kostić2,5, Zoran Perišić2,5, Nebojša Lađević6,7. 1. Center for Anesthesiology and Reanimatology, Clinical Center Nis, Niš, Serbia. 2. Faculty of Medicine, University of Nis, Niš, Serbia. 3. Center for Biochemistry, Clinical Center Nis, Niš, Serbia. 4. Institute for Cardiovascular Diseases, Belgrade, Serbia. 5. Clinic for Cardiovascular Diseases, Clinical Center Nis, Niš, Serbia. 6. Center for Anesthesiology and Reanimatology, Clinical Center of Serbia, Belgrade, Serbia. 7. Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Abstract
OBJECTIVE: We evaluated the utility of preoperative midregional (MR) pro-adrenomedullin (proADM) and cardiac troponin T (TnT) for improved detection of patients at high risk for perioperative cardiac events and mortality after major noncardiac surgery. SUBJECTS AND METHODS: This prospective, single-center, observational study enrolled 79 patients undergoing major noncardiac surgery. After initial clinical assessment (clinical history, physical examination, echocardiogram, blood tests, and chest X-ray), MR-proADM and high-sensitivity TnT (hsTnT) were measured within 48 h prior to surgery by immunoluminometric and electrochemiluminescence immunoassay. Patients were followed by the consulting physician until discharge or up to 14 days in the hospital after surgery. Perioperative cardiac events included myocardial infarction and development or aggravation of congestive heart failure. Data were compared between patients who developed target events and event-free patients. RESULTS: Within 14 days of monitoring, 14 patients (17.72%) developed target events: 9 (11.39%) died and 5 (6.33%) developed cardiovascular events. The average age of the patients was 71.29 ± 6.62 years (range: 55-87). Sex, age, and hsTnT did not significantly differ between groups. MR- proADM concentration was higher in deceased patients (p = 0.01). The upper quartile of MR-proADM was associated with a fatal outcome (66.7 vs. 20.0%, p < 0.01) and with cardiovascular events (64.3 vs. 16.9%, p < 0.01). MR-proADM above the cutoff value (≥0.85) was associated with a fatal outcome (88.9 vs. 20.0%, p < 0.01) and cardiovascular events (71.4 vs. 28.6%, p < 0.01); this association was not observed for hsTnT. CONCLUSION: Preoperative measurement of MR-proADM provides useful information for perioperative cardiac events in high-risk patients scheduled for noncardiac surgery.
OBJECTIVE: We evaluated the utility of preoperative midregional (MR) pro-adrenomedullin (proADM) and cardiac troponin T (TnT) for improved detection of patients at high risk for perioperative cardiac events and mortality after major noncardiac surgery. SUBJECTS AND METHODS: This prospective, single-center, observational study enrolled 79 patients undergoing major noncardiac surgery. After initial clinical assessment (clinical history, physical examination, echocardiogram, blood tests, and chest X-ray), MR-proADM and high-sensitivity TnT (hsTnT) were measured within 48 h prior to surgery by immunoluminometric and electrochemiluminescence immunoassay. Patients were followed by the consulting physician until discharge or up to 14 days in the hospital after surgery. Perioperative cardiac events included myocardial infarction and development or aggravation of congestive heart failure. Data were compared between patients who developed target events and event-free patients. RESULTS: Within 14 days of monitoring, 14 patients (17.72%) developed target events: 9 (11.39%) died and 5 (6.33%) developed cardiovascular events. The average age of the patients was 71.29 ± 6.62 years (range: 55-87). Sex, age, and hsTnT did not significantly differ between groups. MR- proADM concentration was higher in deceased patients (p = 0.01). The upper quartile of MR-proADM was associated with a fatal outcome (66.7 vs. 20.0%, p < 0.01) and with cardiovascular events (64.3 vs. 16.9%, p < 0.01). MR-proADM above the cutoff value (≥0.85) was associated with a fatal outcome (88.9 vs. 20.0%, p < 0.01) and cardiovascular events (71.4 vs. 28.6%, p < 0.01); this association was not observed for hsTnT. CONCLUSION: Preoperative measurement of MR-proADM provides useful information for perioperative cardiac events in high-risk patients scheduled for noncardiac surgery.
Authors: Anne Funke-Kaiser; Aki S Havulinna; Tanja Zeller; Sebastian Appelbaum; Pekka Jousilahti; Erkki Vartiainen; Stefan Blankenberg; Karsten Sydow; Veikko Salomaa Journal: Ann Med Date: 2014-02-10 Impact factor: 4.709
Authors: F Pousset; F Masson; O Chavirovskaia; R Isnard; A Carayon; J L Golmard; P Lechat; D Thomas; M Komajda Journal: Eur Heart J Date: 2000-06 Impact factor: 29.983
Authors: Ganesan Karthikeyan; Ross A Moncur; Oren Levine; Diane Heels-Ansdell; Matthew T V Chan; Pablo Alonso-Coello; Salim Yusuf; Daniel Sessler; Juan Carlos Villar; Otavio Berwanger; Matthew McQueen; Anna Mathew; Stephen Hill; Simon Gibson; Colin Berry; Huei-Ming Yeh; P J Devereaux Journal: J Am Coll Cardiol Date: 2009-10-20 Impact factor: 24.094
Authors: Eric Lim; Li Li Choy; Lydia Flaks; Shafi Mussa; Fillip Van Tornout; Marc Van Leuven; G Wyn Parry Journal: J Cardiothorac Surg Date: 2006-10-23 Impact factor: 1.637
Authors: Adam Csordas; Fabian Nietlispach; Philipp Schuetz; Andreas Huber; Beat Müller; Francesco Maisano; Maurizio Taramasso; Igal Moarof; Slayman Obeid; Barbara E Stähli; Martin Cahenzly; Ronald K Binder; Christoph Liebetrau; Helge Möllmann; Won-Keun Kim; Christian Hamm; Thomas F Lüscher Journal: PLoS One Date: 2015-12-02 Impact factor: 3.240